NRAS and cancer: Fifty-five of 100 cell lines, including several cell lines with neuroblastoma RAS (NRAS) mutations (Figure S2G), had an IC50 less than 10 μM Figures 2D and 2G; Table S4), demonstrating a broad spectrum of activity against cancer cells derived from many different tissues with different mutations.